Melatonin attenuates MPP+-induced neurodegeneration and glutathione impairment in the nigrostriatal dopaminergic pathway.
about
Melatoninergic System in Parkinson's Disease: From Neuroprotection to the Management of Motor and Nonmotor SymptomsMelatonin combats molecular terrorism at the mitochondrial level.Melatonin attenuates MPTP-induced neurotoxicity via preventing CDK5-mediated autophagy and SNCA/α-synuclein aggregation.Melatonin as a neuroprotective agent in the rodent models of Parkinson's disease: is it all set to irrefutable clinical translation?Pharmacological doses of melatonin induce alterations in mitochondrial mass and potential, bcl-2 levels and K+ currents in UVB-exposed U937 cells.MPP+-induced neuronal death in rats involves tyrosine 33 phosphorylation of WW domain-containing oxidoreductase WOX1.Melatonin protects SK-N-SH neuroblastoma cells from amphetamine-induced neurotoxicity.Glutathione depletion-induced apoptosis of Ha-ras-transformed NIH3T3 cells can be prevented by melatonin.Inhibition of platelet aggregation by 1-methyl-4-phenyl pyridinium ion (MPP+) through ATP depletion: Evidence for the reduced platelet activities in Parkinson's disease.Melatonin inhibits manganese-induced motor dysfunction and neuronal loss in mice: involvement of oxidative stress and dopaminergic neurodegeneration.Influence of hydroxyethyl starch on healing of colonic anastomosis in a rat model of peritonitis.Melatonin reduces the neuronal loss, downregulation of dopamine transporter, and upregulation of D2 receptor in rotenone-induced parkinsonian rats.MPP+-Lesioned Mice: an Experimental Model of Motor, Emotional, Memory/Learning, and Striatal Neurochemical Dysfunctions.Melatonin prevents the dynamin-related protein 1-dependent mitochondrial fission and oxidative insult in the cortical neurons after 1-methyl-4-phenylpyridinium treatment.Melatonin synergizes with low doses of L-DOPA to improve dendritic spine density in the mouse striatum in experimental Parkinsonism.
P2860
Q28075345-BEBBBB7A-AF6D-4657-BB27-BD229C35DD33Q34359618-30418CAC-8017-4DCA-8EDC-AAD87DBEB364Q36777303-0DD9D61E-A702-4038-9996-957656771254Q37971339-2106BD97-A3CE-4BA2-A102-1919743AA8CEQ39201841-17F9BF96-855F-47A1-97E2-787C12757965Q39997806-6B41944E-DC7C-42DF-87C1-EC30EDB1C0B3Q40110666-64243346-C78D-44F5-B097-143F3BDF0A21Q40666421-2DD82657-EF21-4712-878C-B67E17D0F7AAQ42167762-CE992ED7-88C0-401B-ACA5-39B39418AD30Q42705031-785BE2D4-DEF6-4FE2-94C3-8342418DB8C7Q43258284-ECFFD704-E930-4695-8587-AED9EE20414EQ46742263-ECF7A190-ABBE-41D8-B4F4-5E3E8C5A0B9EQ48483209-652D0AFB-856A-4DB6-BF63-C955315E8061Q48756200-AE0E22F7-5C65-4BE4-A1B6-B684070FC7C7Q49149998-3B79EAC6-0DBE-49DB-BADA-92712E8B73BC
P2860
Melatonin attenuates MPP+-induced neurodegeneration and glutathione impairment in the nigrostriatal dopaminergic pathway.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Melatonin attenuates MPP+-indu ...... striatal dopaminergic pathway.
@en
Melatonin attenuates MPP+-indu ...... striatal dopaminergic pathway.
@nl
type
label
Melatonin attenuates MPP+-indu ...... striatal dopaminergic pathway.
@en
Melatonin attenuates MPP+-indu ...... striatal dopaminergic pathway.
@nl
prefLabel
Melatonin attenuates MPP+-indu ...... striatal dopaminergic pathway.
@en
Melatonin attenuates MPP+-indu ...... striatal dopaminergic pathway.
@nl
P2093
P2860
P1476
Melatonin attenuates MPP+-indu ...... striatal dopaminergic pathway.
@en
P2093
Eric I-Chian Li
Jih Ing Chuang
Mei Huei Hong
Shur Tzu Chen
P2860
P304
P356
10.1034/J.1600-079X.2002.01871.X
P577
2002-05-01T00:00:00Z